All NewsFDA BriefsOncology IconsSpecial ReportsVoices from the Field
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
All VideosCase-Based Peer PerspectivesExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPivotal Practice Views with the Oncology BrothersPodcastsPrecision Medicine
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
CME/CE
Case-Based Roundtable SeriesClinical TrialsPartnersPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
eNewsletterPrint Subscription
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Biomarker-Driven Lung Cancer
  • GIST
  • HER2-Positive Breast Cancer
  • Chronic Lymphocytic Leukemia
  • Small Cell Lung Cancer
  • Renal Cell Carcinoma
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CME/CE
Advertisement

Rajneesh Nath, MD

home / authors / rajneesh-nath-md

Articles

Advertisement

Future Directions for Elderly Patients With Relapsed/Refractory AML

Future Directions for Elderly Patients With Relapsed/Refractory AML

April 5th 2022

Rajneesh Nath, MD, discusses what is in store regarding treatment for elderly patients with relapsed/refractory acute myeloid leukemia.


SIERRA Trial Delivers Initial Data for Older Patients With AML

SIERRA Trial Delivers Initial Data for Older Patients With AML

May 1st 2020

Rajneesh Nath, MD, discusses the early results of the phase III SIERRA trial investigating the efficacy of Iomab-B and protocol-specified allogeneic hematopoietic stem cell transplant versus the standard of care in older patients with active, relapsed or refractory acute myeloid leukemia.


Evaluating Older Patients With Acute Myeloid Leukemia in SIERRA Trial

Evaluating Older Patients With Acute Myeloid Leukemia in SIERRA Trial

April 8th 2020

Rajneesh Nath, MD, discusses the rationale for phase III SIERRA trial, which evaluated the anti-CD45 monoclonal antibody apamistamab followed by fludarabine/total body irradiation and allogeneic hematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukemia.


An Overview of the Ongoing SIERRA Trial in Relapsed/Refractory AML

An Overview of the Ongoing SIERRA Trial in Relapsed/Refractory AML

December 19th 2018

Rajneesh Nath, MD, director, stem cell transplant and acute leukemia program, Banner MD Anderson Cancer Center, discusses the ongoing&nbsp;phase III SIERRA trial, which is evaluating targeted conditioning of Iomab-B prior to allogeneic hematopoietic cell transplantation versus conventional care in patients with relapsed/refractory acute myeloid leukemia (AML).<br /> &nbsp;

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.